Genotype and risk of tumour rupture in gastrointestinal stromal tumour

Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine

(2016) T. Hølmebakk et al.   BRITISH JOURNAL OF SURGERY

KIT Exon 11 Codons 557-558 Deletion Mutation Promotes Liver Metastasis Through the CXCL12/CXCR4 Axis in Gastrointestinal Stromal Tumors

(2016) H.-C. Wang et al.   CLINICAL CANCER RESEARCH

Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group

(2016) Anna Patrikidou et al.   EUROPEAN JOURNAL OF CANCER

Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas

(2015) Paolo G. Casali et al.   JOURNAL OF CLINICAL ONCOLOGY

Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2014)   ANNALS OF ONCOLOGY

Analysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy for Gastrointestinal Stromal Tumors

(2014) Brian K. Bednarski et al.   ANNALS OF SURGICAL ONCOLOGY

Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib

(2014) Heikki Joensuu et al.   CANCER

Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST

(2014) A. Wozniak et al.   CLINICAL CANCER RESEARCH

Re-appraisal of risk classifications for primary gastrointestinal stromal tumors (GISTs) after complete resection: indications for adjuvant therapy

(2014) Yoshitomo Yanagimoto et al.   Gastric Cancer

Intermittent and continuous imatinib in a human GIST xenograft model carryingKITexon 17 resistance mutation D816H

(2013) Mona-Elisabeth Revheim et al.   ACTA ONCOLOGICA

Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor

(2013) Ronald P. DeMatteo et al.   ANNALS OF SURGERY

Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience

(2013) Piotr Rutkowski et al.   ANNALS OF SURGICAL ONCOLOGY

Gastrointestinal stromal tumour

(2013) Heikki Joensuu et al.   LANCET

Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib

(2012) R. Tielen et al.   EJSO

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor

(2012) Heikki Joensuu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience

(2011) A. Wozniak et al.   ANNALS OF ONCOLOGY

Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132

(2011) Dian Wang et al.   ANNALS OF SURGICAL ONCOLOGY

Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour

(2010) P. Hohenberger et al.   BRITISH JOURNAL OF SURGERY

Prognosis and predictive value of KIT exon 11 deletion in GISTs

(2009) J-B Bachet et al.   BRITISH JOURNAL OF CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665

(2008) Burton L. Eisenberg et al.   JOURNAL OF SURGICAL ONCOLOGY